Lördag 1 November | 03:28:03 Europe / Stockholm

Prenumeration

2025-10-30 09:55:00

Following a quarter marked by clinical progress, increased operational focus on value-creating programs and a strengthened financial position, BioInvent is stepping up preparations for the next phase of its development. According to CEO Martin Welschof, resources are now being directed toward the company’s most promising projects ahead of several key milestones in 2025 and 2026.

Read the article at biostock.se:

BioInvent sharpens focus on top clinical candidates
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/